Accessibility Menu
Grifols logo

Grifols(OTC) GIKLY

Market Cap$4.85BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2009)+61%
5 Year-50%
1 Year-22%
1 Month+14%
$5.75
-0.59%
-0.03Today
Grifols last closing stock price
MetricPriceDate
Last closeUSD 5.752026-08-27
Grifols stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+13.83%USD 5.052026-08-17
1 month+13.83%USD 5.052026-07-27
3 month+1.93%USD 5.642026-05-29
Year to date-5.77%USD 6.102025-12-08
1 year-21.6%USD 7.332025-08-15
3 year-16.16%USD 6.852023-08-28
5 year-50.05%USD 11.502021-08-27
Since inception+60.8%USD 3.572009-07-21

Grifols Financials at a Glance

Market Cap

$4.85BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€7.43B

Net Income (TTM)

€452.39M

EPS (TTM)

$0.39

P/E Ratio

14.83

Dividend

$0.05

Beta (Volatility)

0.36 (Low)

Price

$5.75

Volume

1,689

Open

$5.75

Previous Close

$5.75

Daily Range

$5.75 - $5.75

52-Week Range

$5.06 - $7.14

Estimated Earnings Date

Nov 10, 2026

GIKLY News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Grifols

Grifols, S.A. is a global healthcare company specializing in the acquisition, production, processing, and distribution of therapeutic goods, particularly plasma-derived medicines. Established in 1940 and headquartered in Barcelona, Spain, Grifols operates across several key divisions, including Bioscience, Hospital, Diagnostic, and Bio Supplies.

Products and Services
  • Plasma-derived medications for chronic and life-threatening conditions
  • Non-biological pharmaceuticals and medical supplies for hospitals
  • Diagnostic tools for healthcare professionals across patient care journeys
Growth Outlook
  • Revenue growth of 8.5% year-over-year in Q2 2026
  • Strong demand for plasma-derived therapies driving market expansion
  • Investment in R&D to enhance product offerings and innovation
Financial Highlights
  • Q2 2026 net income of €154 million, reflecting a 10% increase
  • TTM revenue of €7.4 billion, showcasing consistent growth
  • Operating income margin of 17.6% in Q2 2026, indicating operational efficiency
Grifols, S.A. has established itself as a leader in the healthcare sector, particularly in the field of plasma-derived therapies. The company's diverse product portfolio addresses a wide range of medical needs, from chronic conditions to diagnostic tools. Recent financial performance highlights a robust growth trajectory, with significant revenue increases and a strong operating income margin. The ongoing investment in research and development positions Grifols to capitalize on emerging opportunities in the healthcare market, making it an attractive option for potential investors.
AI Generated • Aug 28, 2026

Industry

Biotechnology

Sector

Health Care

Employees

25,258

CEO

Nacho Abia Buenache, MBA

Website

www.grifols.com

Headquarters

Barcelona, CT 08174, ES

GIKLY Financials

Key Financial Metrics (TTM)

Gross Margin

37.23%

Operating Margin

16.66%

Net Income Margin

6.09%

Return on Equity

8.43%

Return on Capital

8.39%

Return on Assets

2.25%

Earnings Yield

6.74%

Dividend Yield

0.82%

Payout Ratio

28.31%

Stock Overview

Market Cap

$4.85BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

844.72M

Volume

1.69K

Avg. Volume

64.047

Financials (TTM)

Gross Profit

€2.77B

Operating Income

€1.24B

EBITDA

€1.62B

Operating Cash Flow

€1.08B

Capital Expenditure

-€325.33M

Free Cash Flow

€757.52M

Cash & ST Invst.

€529.00M

Total Debt

€8.52B

Grifols Performance Analysis

Grifols annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 6,373,073,5749.3%
20232023-12-31EUR 7,126,689,18911.8%
20242024-12-31EUR 7,801,566,9409.5%
20252025-12-31EUR 8,491,420,5008.8%
Grifols sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-1.4%
Q42025-12-315.2%
Q12026-03-31-12.0%
Q22026-06-308.5%
Grifols annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR 0.16-1.9%
20232023-12-31EUR 0.03-79.1%
20242024-12-31EUR 0.12270.0%
20252025-12-31EUR 0.33167.3%
Grifols sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3011.8%
Q42025-12-31-26.3%
Q12026-03-31-21.4%
Q22026-06-30109.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€1.87B

-0.9%

Gross Profit

€704.00M

-5.4%

Gross Margin

37.57%

N/A

Market Cap

$4.85BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$192.17K

N/A

Employees

25,258

N/A

Net Income

€154.00M

+31.6%

EBITDA

€535.00M

+54.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€529.00M

-6.5%

Total Debt

€8.52B

-3.4%

Accounts Receivable

€1.19B

-5.1%

Inventory

€3.49B

+4.3%

Long Term Debt

€8.10B

-3.9%

Short Term Debt

€420.00M

+6.6%

Return on Assets

2.25%

N/A

Return on Invested Capital

6.93%

N/A

Free Cash Flow

€108.00M

+13.7%

Operating Cash Flow

€227.00M

+46.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CHJTFCSPC Pharmaceutical Group Limited
$1.11+0.00%
SNNUFSmith & Nephew plc
$15.48+0.00%
FMCQFFresenius Medical Care AG
$51.44+0.00%
ORINYOrion Oyj
$45.77+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.15-0.12%
NVDANvidia
$230.36+0.01%
PATHUiPath
$15.19-0.17%
INTCIntel
$95.80+0.05%

Questions About GIKLY

What is the current price of Grifols?

Grifols is trading at $5.75 per share.

What is the 52-week range for Grifols?

Over the past 52 weeks, Grifols has traded between $5.06 and $7.14.

How much debt does Grifols have?

As of the most recent reporting period, Grifols reported total debt of €9.74B.

How much cash does Grifols have on hand?

Grifols reported €586.51M in cash and cash equivalents in its most recent financial results.

What is Grifols’s dividend yield?

Grifols currently has a dividend yield of 0.82%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services